Fortinet Inc vs Merck & Co., Inc. — how do they compare? Fortinet Inc trades at $189.68 (market cap $138.88B), while Merck & Co., Inc. trades at $142.16 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 2.5× Fortinet Inc's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Merck & Co., Inc. for 98 Days on average.
| FTNT | MRK | |
|---|---|---|
Market Cap | $138.88B | $352.29B |
Volume | 3,857,161 | 6,348,796 |
Sector | Technology | Health |
52-Week High | $191.27 | $156.43 |
52-Week Low | $75.23 | $82.49 |
Typical Hold Time | 72 Days | 98 Days |
Enterprise Value | $135.30B | $399.05B |
Dividend Yield | — | 2.38% |
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $189.10, down 1.13% today but remains near recent highs with strong technical momentum. The cybersecurity leader demonstrates robust fundamentals with 28.17% net margins and consistent earnings beats, though valuation ratios appear elevated (P/E 66.88, P/S 18.81). Recent news highlights AI security demand driving platform growth, with the company scheduled to report Q3 2026 results on October 28.
Fortinet presents growth potential through cybersecurity market leadership and AI-driven demand, but faces valuation concerns and competitive pressures. The stock's technical strength and fundamental execution support upside, though high multiples require sustained growth to justify current levels. Key risks include execution missteps and market volatility amid elevated expectations.
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →